Reshma Rangwala, EVP & Chief Medical Officer at Karyopharm Therapeutics Inc. (KPTI), sold 449 shares at $8.94 ($4K) on 2026-04-21, disclosed to the SEC on 2026-04-22.
Seasonal sale ($4k) by EVP & Chief Medical Officer — this insider has traded KPTI in April in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| Filing → |
| KPTI | SELL | 2025-09-16 | $3K | — | Filing → |
| KPTI | SELL | 2025-04-24 | $3K | — | Filing → |
| KPTI | SELL | 2025-03-06 | $23K | — | Filing → |